Last 48 quarters of trend data · Healthcare · Neuroscience Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 10.28 | 16.25 | 35.14 | 278.25 | 4.17 | 12.70 | 33.70 | 37.75 | 5.33 | 19.23 | 20.31 | 46.22 | 27.96 | — | 880.51 | — | — | — | — | — | — |
| — | +27.9% | +4.3% | +637.1% | -21.8% | -33.9% | +65.9% | -18.3% | -80.9% | — | -97.7% | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 3.02 | 2.58 | 3.55 | 3.59 | 4.03 | 3.27 | 3.44 | 2.85 | 2.94 | 2.55 | 2.79 | 3.74 | 5.64 | 4.04 | 5.98 | 6.44 | 4.72 | 5.06 | 4.23 | 8.45 | 7.18 |
| — | -21.0% | +3.3% | +25.8% | +37.1% | +28.0% | +23.2% | -23.8% | -47.9% | -36.9% | -53.3% | -41.9% | +19.4% | -20.2% | +41.3% | -23.8% | -34.2% | -0.1% | -50.2% | -12.7% | -59.2% | |
| P/B Ratio | 2.96 | 2.55 | 3.35 | 3.08 | 3.73 | 3.97 | 4.42 | 3.64 | 4.17 | 4.43 | 5.23 | 6.64 | 12.07 | 9.45 | 9.99 | 8.16 | 6.44 | 6.22 | 5.24 | 8.78 | 6.94 |
| — | -35.8% | -24.4% | -15.4% | -10.5% | -10.3% | -15.3% | -45.2% | -65.5% | -53.1% | -47.7% | -18.6% | +87.5% | +51.9% | +90.7% | -7.1% | -7.2% | +32.2% | -24.4% | +23.7% | -48.9% | |
| P/FCF | 32.82 | 86.13 | 8.78 | 33.41 | — | 12.32 | 5.60 | — | 19.11 | 10.11 | 26.99 | 26.49 | 15.26 | — | 120.50 | — | — | — | — | — | — |
| — | +599.1% | +56.9% | — | — | +21.8% | -79.3% | — | +25.2% | — | -77.6% | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 25.05 | 10.21 | 24.77 | — | 54.78 | 22.21 | 24.36 | 29.49 | 4.39 | 17.90 | 19.55 | 35.39 | 34.73 | — | 203.19 | — | — | — | — | — | — |
| — | -54.0% | +1.7% | — | +1148.7% | +24.1% | +24.6% | -16.7% | -87.4% | — | -90.4% | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 33.49 | 10.21 | 34.78 | 226.89 | 42.28 | 19.28 | 21.39 | 23.61 | 99.64 | 15.78 | 17.35 | 34.95 | 36.36 | — | 321.35 | — | — | — | — | — | — |
| — | -47.0% | +62.6% | +861.1% | -57.6% | +22.1% | +23.3% | -32.4% | +174.1% | — | -94.6% | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 91.7% | 89.7% | 90.8% | 90.8% | 90.8% | 92.2% | 92.2% | 91.7% | 91.6% | 92.5% | 92.5% | 88.8% | 92.3% | 93.1% | 95.5% | 98.6% | 98.2% | 98.4% | 98.0% | 97.4% | 98.0% |
| — | -2.7% | -1.5% | -1.0% | -0.9% | -0.3% | -0.3% | +3.2% | -0.7% | -0.7% | -3.2% | -9.9% | -6.1% | -5.4% | -2.6% | +1.2% | +0.2% | +3.6% | +2.7% | +1.9% | +2.5% | |
| Operating Margin | 9.8% | 21.0% | 12.3% | -1.7% | 6.1% | 12.8% | 12.2% | 7.9% | 59.1% | 12.6% | 12.6% | 7.4% | 15.1% | -27.3% | 1.8% | -45.2% | -33.7% | -23.6% | -25.0% | -97.9% | -34.2% |
| — | +63.3% | +0.4% | -121.8% | -89.6% | +1.5% | -2.7% | +6.8% | +291.0% | +146.3% | +584.4% | +116.3% | +144.8% | -15.6% | +107.3% | +53.8% | +1.2% | -103.1% | +34.1% | -56.2% | +38.5% | |
| Net Margin | 36.5% | 15.6% | 10.2% | 1.4% | 96.3% | 25.8% | 10.1% | 7.8% | 55.4% | 13.1% | 13.8% | 8.0% | 19.8% | -30.8% | 0.7% | -36.3% | -30.6% | -20.8% | -25.3% | -97.9% | -33.0% |
| — | -39.3% | +1.5% | -82.5% | +74.0% | +96.9% | -27.0% | -3.4% | +179.3% | +142.5% | +1946.8% | +122.1% | +164.8% | -48.0% | +102.7% | +62.9% | +7.2% | -89.3% | +33.6% | -57.0% | +40.3% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 39.9% | 4.0% | 2.5% | 0.3% | 25.5% | 8.3% | 3.4% | 2.5% | 21.9% | 6.0% | 6.8% | 3.7% | 11.5% | -17.2% | 0.3% | -11.1% | -10.1% | -6.3% | -7.7% | -22.9% | -7.8% |
| — | -51.8% | -26.6% | -88.4% | +16.2% | +37.8% | -50.7% | -31.4% | +90.2% | +134.8% | +2253.6% | +133.3% | +214.2% | -172.2% | +103.7% | +51.6% | -29.8% | -147.3% | -1.0% | -108.6% | +25.3% | |
| ROA | 28.4% | 3.0% | 1.9% | 0.2% | 18.9% | 5.6% | 2.3% | 1.6% | 13.3% | 3.5% | 3.8% | 2.1% | 6.6% | -10.2% | 0.2% | -6.9% | -7.0% | -4.5% | -5.5% | -17.1% | -6.1% |
| — | -46.1% | -16.8% | -86.0% | +42.3% | +62.1% | -40.1% | -20.7% | +100.3% | +133.9% | +2099.6% | +129.8% | +194.6% | -128.5% | +103.1% | +59.5% | -15.3% | -123.1% | +7.3% | -97.6% | +28.1% | |
| ROIC | 10.0% | 5.0% | 2.8% | -0.3% | 1.4% | 4.0% | 4.0% | 2.7% | 24.6% | 5.5% | 6.4% | 3.7% | 8.4% | -13.0% | 0.9% | -16.4% | -10.1% | -6.7% | -7.6% | -22.2% | -6.7% |
| — | +26.0% | -28.6% | -112.1% | -94.2% | -26.7% | -38.0% | -26.5% | +191.5% | +142.1% | +586.7% | +122.5% | +183.2% | -94.1% | +112.2% | +26.5% | -50.8% | -162.9% | +17.8% | -54.2% | +59.8% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.05 | 0.06 | 0.04 | 0.04 | 0.06 | 0.07 | 0.07 | 0.07 | 0.09 | 0.11 | 0.13 | 0.13 | 0.16 | 0.15 | 0.16 | 0.15 | 0.15 | 0.15 | 0.14 | 0.12 |
| — | -13.3% | -17.4% | -44.4% | -40.1% | -30.1% | -38.7% | -43.1% | -46.4% | -45.8% | -24.9% | -20.6% | -14.4% | +6.6% | +1.5% | +11.8% | +30.0% | +27.5% | +24.2% | +26.4% | +50.7% | |
| Debt / EBITDA | 0.45 | 0.89 | 1.80 | — | 2.57 | 1.42 | 1.59 | 2.52 | 0.33 | 1.44 | 1.75 | 2.88 | 1.56 | — | 12.25 | — | — | — | — | — | — |
| — | -36.9% | +13.0% | — | +684.2% | -1.9% | -8.7% | -12.4% | -79.1% | — | -85.7% | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.83 | 3.82 | 3.39 | 3.59 | 3.83 | 3.02 | 2.91 | 2.88 | 2.38 | 2.29 | 2.16 | 2.04 | 2.42 | 2.38 | 2.62 | 2.24 | 4.04 | 4.47 | 4.53 | 4.53 | 6.43 |
| — | +26.5% | +16.4% | +24.6% | +61.3% | +31.7% | +34.9% | +40.9% | -1.9% | -3.8% | -17.7% | -8.9% | -40.1% | -46.8% | -42.1% | -50.5% | -37.1% | -38.4% | -33.2% | -26.4% | -5.0% | |
| Quick Ratio | 3.71 | 3.70 | 3.30 | 3.48 | 3.71 | 2.94 | 2.83 | 2.80 | 2.32 | 2.11 | 1.95 | 1.86 | 2.28 | 2.28 | 2.57 | 2.21 | 3.99 | 4.42 | 4.47 | 4.47 | 6.35 |
| — | +25.9% | +16.5% | +24.3% | +59.8% | +38.9% | +45.5% | +51.1% | +1.7% | -7.4% | -24.4% | -16.2% | -42.8% | -48.4% | -42.5% | -50.5% | -37.2% | -37.7% | -32.9% | -26.3% | -5.0% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ACAD stock.
ACADIA Pharmaceuticals Inc.'s current P/E is 10.3x. The average P/E over the last 4 quarters is 83.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
ACADIA Pharmaceuticals Inc.'s current operating margin is 9.8%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking ACADIA Pharmaceuticals Inc.'s business trajectory between earnings reports.